Preston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stock
Preston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stock
Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research note on Wednesday, November 16th.Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 380,605 shares of the firm's stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $156,048.05. Following the completion of the transaction, the chief executive officer now owns 541,905 shares of the company's stock, valued at approximately $222,181.05. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
梅塔克林公司（NASDAQ：MTCR-獲取評級）首席執行官普雷斯頓·克拉森於 1 月 26 日（星期四）在一次交易中出售了該公司股票的 380,605 股。該股票以 0.41 美元的平均價格出售，總價值 156,048.05 美元。交易完成後，首席執行官現擁有該公司股份的 541,905 股，價值約為 222,181.05 元。該銷售在向 SEC 提交的文件中披露，該文件可通過以下方式獲得 此超連結。
Metacrine Stock Performance
甲基林股票表現
NASDAQ MTCR opened at $0.48 on Friday. The stock has a 50-day simple moving average of $0.43 and a two-hundred day simple moving average of $0.45. The firm has a market capitalization of $20.44 million, a P/E ratio of -0.47 and a beta of -0.92. Metacrine, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $0.68. The company has a debt-to-equity ratio of 0.34, a quick ratio of 12.15 and a current ratio of 12.15.
納斯達克 MTCR 在周五開盤 0.48 美元。該股有一個 50 天的簡單移動平均線 0.43 美元和 200 天的簡單移動平均線 0.45 美元。該公司的市值為 20.44 萬美元，市盈率為 -0.47，貝塔值為 -0.92。梅塔克林擁有五十兩周低點 0.30 美元，五十二周高點為 0.68 美元。該公司的債務與權益比率為 0.34，快速比率為 12.15，流動比率為 12.15。
Metacrine (NASDAQ:MTCR – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts forecast that Metacrine, Inc. will post -0.62 earnings per share for the current year.
甲基林（NASDAQ：MTCR-獲取評分）最近一次發布了其季度收益數據，週一，11 月 14 日。該公司報告了本季度每股盈利（0.13 美元），缺少分析師的共識估計為（0.11 美元）（0.02 美元）。平均而言，股票分析師預測，本年度 Metacrine Inc. 將公佈每股盈利 -0.62。
Hedge Funds Weigh In On Metacrine
對沖基金對甲基林的權衡
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research note on Wednesday, November 16th.
此外，HC 溫賴特在 11 月 16 日（星期三）的一份研究報告中重申了對米克林股份的「中性」評級。
About Metacrine
關於梅塔克林
(Get Rating)
(取得評分)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642，該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年，總部位於加利福尼亞州聖地牙哥。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 獲取有關二甲基林（MTCR）的研究報告的免費副本
- 市場節拍週的回顧 — 1/23-1/27
- 為什麼清醒在一天內飆升近 100％
- 乘坐這些鐵路股票以獲得增長和收入
- ASML 今年看到籌碼需求上升，提高了銷售觀點
- KLA 公司：陷入困境的半市場中的實力
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
